Compare Adaptive Biotechnologies Corp (ADPT) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Robinhood Markets, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Robinhood Markets, Inc. trades at $113.09 (market cap $101.67B). The key difference: Robinhood Markets, Inc. is far larger — about 30.5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | HOOD | |
|---|---|---|
Market Cap | $3.33B | $101.67B |
Sector | Health | Technology |
52-Week High | $22.37 | $152.46 |
52-Week Low | $10.24 | $65.16 |
Enterprise Value | $3.19B | $102.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Robinhood (HOOD) trades at $112.90, up 0.15% with strong technical momentum as it approaches resistance near $116. The stock shows robust fundamentals with 2025 revenue reaching $4.47 billion and net income of $1.88 billion, though valuation metrics remain elevated with a P/E of 57.06. Recent positive sentiment stems from international expansion and new product launches, including AI-powered trading tools and the Trump Accounts program announced July 2026.
Outlook remains positive with 73% analyst buy ratings and $108.13 consensus target, though the stock trades above target. Key opportunities include continued revenue growth and banking expansion, while risks involve high valuation multiples and cryptocurrency revenue volatility. Q2 2026 earnings on July 29 will be crucial for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
